Saudi Arabia Generic Drugs Market Outlook and Forecast 2026–2034

Saudi Arabia Generic Drugs Market

Saudi Arabia Generic Drugs Market is anticipated to witness significant growth during the forecast period, driven by increasing healthcare expenditure, rising prevalence of chronic diseases, government initiatives promoting affordable medicines, and expanding domestic pharmaceutical manufacturing capabilities. The market is projected to grow from US$ 4.37 Billion in 2025 to US$ 8.75 Billion by 2034, registering a Compound Annual Growth Rate (CAGR) of 8.02% during 2026–2034. Growing demand for cost-effective treatment options will continue to support market expansion.

Saudi Arabia Generic Drugs Market Overview

Generic drugs are pharmaceutical products that contain the same active ingredients, dosage form, strength, safety profile, and therapeutic effectiveness as their branded counterparts. These medications are introduced after the patent protection of original branded drugs expires, allowing manufacturers to produce more affordable alternatives. Generic drugs undergo rigorous regulatory evaluations to ensure they meet established standards for quality, efficacy, and safety. They are widely used to treat various acute and chronic conditions, including cardiovascular diseases, diabetes, infections, cancer, respiratory disorders, and neurological conditions. By offering cost-effective treatment options, generic medicines play a vital role in improving healthcare accessibility and reducing overall healthcare expenditure.

In Saudi Arabia, generic drugs have gained substantial popularity due to rising healthcare costs, increasing prevalence of chronic diseases, and government initiatives aimed at promoting affordable healthcare solutions. The Saudi government has encouraged the use of generic medicines through healthcare reforms, local pharmaceutical manufacturing initiatives, and regulatory support. Growing awareness among healthcare providers and patients, combined with efforts to strengthen domestic pharmaceutical production under Vision 2030, continues to drive the adoption and expansion of the generic drugs market across the Kingdom.

Generic Drug Launches in Saudi Arabia

• Pantoprazole (2025 – SFDA Approval)
  Proton pump inhibitor generic launched for GERD, ulcers, and acid-related disorders in hospitals and retail pharmacies.
• Linagliptin (2025 – SFDA Approval)
  Oral anti-diabetic generic introduced for Type 2 diabetes management, widely used in combination therapy.
• Sitagliptin (2025 – SFDA Approval)
  DPP-4 inhibitor generic used for glycemic control in diabetic patients.
• Losartan Potassium (2025 – SFDA Approval)
  Anti-hypertensive generic widely used for blood pressure control and kidney protection in diabetic patients.
• Ambrisentan Generic (2025 – SFDA Approval)
  Pulmonary arterial hypertension treatment introduced as a multisource generic alternative.
• Eltrombopag Olamine (2025 – SFDA Approval)
  Used for immune thrombocytopenia treatment, improving platelet counts in chronic conditions.
• Dabigatran Etexilate (2025 – SFDA Approval)
  Oral anticoagulant generic for prevention of stroke and treatment of thromboembolic disorders.
• Amisulpride (2025 – SFDA Approval)
  Generic antipsychotic used for schizophrenia and psychiatric disorder management.
• Tigecycline (2025 – SFDA Approval)
  Broad-spectrum antibiotic generic used for complicated bacterial infections.
• Paricalcitol (2025 – SFDA Approval)
  Generic injectable used for secondary hyperparathyroidism in chronic kidney disease patients.

Saudi Arabia – A Rapidly Emerging Leader in Healthcare Delivery

• The government now permits 100% foreign ownership of healthcare facilities, including hospitals, polyclinics, telemedicine, and telehealth centers, encouraging international investment.
• Under Vision 2030, Saudi Arabia aims to increase private sector participation in healthcare from 40% to 65% by 2030.
• Non-communicable diseases (NCDs) account for approximately 70% of all deaths in Saudi Arabia, increasing demand for specialized healthcare services and advanced treatment solutions.
• Saudi Arabia's population is expected to increase from 32 million in 2023 to 35 million by 2028, while the elderly population is projected to grow at an 11% CAGR, creating additional healthcare demand.
• The Kingdom is investing heavily in digital health infrastructure, including telemedicine, electronic health records (EHRs), and advanced healthcare IT systems.
• Saudi Arabia is positioning itself as a medical tourism hub, focusing on specialties such as oncology, cardiology, fertility treatment, and cosmetic surgery.
• The government plans to privatize 290 hospitals and 2,300 primary healthcare centers as part of its healthcare transformation strategy.
• To meet international healthcare standards, Saudi Arabia plans to add more than 84,000 hospital beds, increasing the private sector's share of hospital capacity from 23% in 2023 to 68% by 2030.
• The Kingdom aims to recruit approximately 175,000 healthcare professionals by 2030, including 69,000 doctors, 64,000 nurses, and 42,000 allied health professionals.
• The Healthcare Sector Transformation Program (HSTP) focuses on creating an integrated, efficient, digitally enabled, and financially sustainable healthcare system.
• Major investment opportunities exist in greenfield healthcare projects, public-private partnerships (PPPs), medical cities, specialized healthcare services, and healthcare infrastructure development.
• Saudi Arabia's healthcare transformation strategy presents substantial opportunities for investors, healthcare providers, technology companies, and strategic partners worldwide.

Source: Praxis

Market Catalysts of the Saudi Arabia Generic Drugs Market

Rising Healthcare Expenditure and Increasing Prevalence of Chronic Diseases

One of the primary growth drivers of the Saudi Arabia generic drugs market is the increasing burden of chronic diseases coupled with rising healthcare expenditure. The growing prevalence of conditions such as diabetes, cardiovascular diseases, hypertension, cancer, and respiratory disorders has significantly increased the demand for long-term and cost-effective treatment options. Generic drugs offer therapeutic efficacy comparable to branded medications while substantially reducing treatment costs, making them an attractive option for both healthcare providers and patients. Saudi Arabia’s aging population and changing lifestyle patterns have further contributed to the increasing incidence of chronic illnesses, creating sustained demand for affordable pharmaceutical products. Additionally, healthcare institutions and insurance providers are increasingly encouraging the use of generic medications to control overall healthcare spending. As the healthcare system continues to expand and patient awareness regarding affordable treatment alternatives increases, the adoption of generic drugs is expected to accelerate, contributing significantly to the long-term growth of the Saudi Arabian pharmaceutical market.

Government Support and Vision 2030 Healthcare Reforms

Government initiatives and healthcare reforms under Saudi Vision 2030 represent a major driver for the expansion of the generic drugs market. The Saudi government is actively promoting pharmaceutical self-sufficiency, healthcare accessibility, and cost optimization through various regulatory and industrial development programs. Authorities have implemented policies encouraging the prescription and utilization of generic medicines to reduce dependence on expensive imported branded pharmaceuticals and improve healthcare affordability. Furthermore, investments in domestic pharmaceutical manufacturing, research and development, and regulatory modernization have strengthened the country’s pharmaceutical ecosystem. Public healthcare institutions increasingly prioritize generic medicines within procurement programs to optimize healthcare budgets while maintaining treatment quality. The government’s efforts to attract foreign pharmaceutical investments and establish strategic partnerships with international manufacturers have also accelerated local production capabilities. These initiatives support market growth while enhancing drug availability, strengthening supply chain resilience, and advancing Saudi Arabia’s objective of becoming a leading regional pharmaceutical manufacturing hub.

Expansion of Domestic Pharmaceutical Manufacturing and Generic Drug Production

The rapid expansion of domestic pharmaceutical manufacturing capacity is significantly contributing to the growth of the Saudi Arabia generic drugs market. Local pharmaceutical companies are increasingly investing in advanced production facilities, manufacturing technologies, and quality assurance systems to meet rising domestic demand and reduce import dependency. Government incentives, industrial development programs, and favorable regulatory policies have encouraged both domestic and international pharmaceutical companies to establish manufacturing operations within the Kingdom. Local production of generic drugs offers several advantages, including lower production costs, improved supply chain efficiency, faster market access, and greater compliance with national healthcare objectives. Additionally, increasing partnerships between Saudi pharmaceutical companies and global manufacturers facilitate technology transfer, product diversification, and capacity expansion. The growing emphasis on pharmaceutical localization under Vision 2030 is expected to strengthen the country’s generic drug manufacturing capabilities further. This expansion not only supports healthcare affordability but also enhances Saudi Arabia’s competitiveness within the regional pharmaceutical industry.

Challenges of the Saudi Arabia Generic Drugs Market

Strong Brand Preference and Limited Consumer Awareness

One of the major challenges affecting the Saudi Arabia generic drugs market is the continued preference for branded pharmaceutical products among both healthcare professionals and patients. Many consumers perceive branded medicines as being more effective, safer, or of higher quality despite generic drugs meeting equivalent regulatory standards for efficacy and safety. This perception often influences prescribing behavior and purchasing decisions, limiting the broader adoption of generic alternatives. Additionally, limited public awareness regarding the benefits, effectiveness, and cost advantages of generic medications continues to hinder market penetration. Healthcare providers may also remain cautious about substituting branded therapies with generic alternatives in certain therapeutic categories. Overcoming these perceptions requires sustained educational initiatives, increased physician engagement, public awareness campaigns, and regulatory efforts to strengthen confidence in generic medicines. Addressing these behavioral and perception-based barriers remains essential for expanding generic drug utilization and maximizing healthcare cost savings within Saudi Arabia.

Regulatory Complexity and Intense Market Competition

The Saudi Arabia generic drugs market faces challenges related to regulatory requirements, pricing pressures, and increasing market competition. Generic drug manufacturers must comply with stringent regulatory approval processes, bioequivalence testing standards, quality assurance requirements, and product registration procedures before entering the market. These requirements can increase development costs and extend product commercialization timelines. Additionally, the growing number of domestic and international pharmaceutical companies operating in the Saudi market has intensified competition, resulting in pricing pressure and reduced profit margins for manufacturers. Companies must continuously invest in product quality, manufacturing efficiency, regulatory compliance, and market differentiation strategies to maintain competitiveness. Furthermore, fluctuations in raw material costs and global supply chain disruptions can impact production economics and product availability. Successfully navigating these regulatory and competitive challenges will be critical for sustaining profitability and supporting the long-term growth of the generic drugs market in Saudi Arabia.

Saudi Arabia Simple Generic Drugs Market

The simple generic drugs market represents a substantial segment of the pharmaceutical industry in Saudi Arabia due to the widespread demand for affordable and commonly prescribed medications. Simple generics are pharmaceutical products with straightforward formulations, conventional manufacturing processes, and delivery mechanisms that closely replicate the original branded medicines after patent expiration. These medications are extensively utilized for the treatment of common health conditions such as pain management, infections, hypertension, diabetes, and gastrointestinal disorders. Their relatively lower manufacturing complexity and reduced research and development requirements enable pharmaceutical companies to offer cost-effective therapeutic solutions while maintaining regulatory compliance and treatment efficacy. The Saudi government actively supports the use of simple generic drugs through pricing regulations, healthcare reimbursement policies, and public procurement programs aimed at reducing overall healthcare expenditure. Additionally, their broad availability across hospitals, clinics, and retail pharmacies has contributed to increased patient acceptance and market penetration, making simple generic drugs an important foundation of Saudi Arabia’s healthcare system.

Saudi Arabia Specialty Generic Drugs Market

The specialty generic drugs market in Saudi Arabia is experiencing significant growth due to increasing demand for affordable treatment options for complex and chronic diseases. Specialty generics include highly specialized pharmaceutical products used in therapeutic areas such as oncology, autoimmune disorders, rare diseases, and advanced chronic conditions. These medications require sophisticated manufacturing technologies, specialized regulatory approvals, and advanced quality assurance processes due to their complex formulations and delivery mechanisms. Rising incidences of chronic illnesses and increasing healthcare expenditure have encouraged the adoption of specialty generics as cost-effective alternatives to expensive branded biologics and specialty medicines. Pharmaceutical companies operating in Saudi Arabia are increasingly investing in research, manufacturing capabilities, and strategic collaborations to strengthen their presence in this high-value segment. Furthermore, government initiatives promoting pharmaceutical localization and healthcare affordability have accelerated market development. As healthcare providers and insurance systems seek to optimize treatment costs while maintaining clinical outcomes, specialty generics are expected to become an increasingly important component of Saudi Arabia’s pharmaceutical market.

Saudi Arabia Oral Generic Drugs Market

The oral generic drugs market remains the largest and most widely utilized segment within Saudi Arabia’s generic pharmaceutical industry. Oral dosage forms, including tablets, capsules, syrups, and oral suspensions, continue to dominate due to their convenience, patient acceptance, ease of administration, and cost-effectiveness. These products are extensively prescribed across numerous therapeutic categories, including cardiovascular diseases, diabetes, infectious diseases, gastrointestinal disorders, and neurological conditions. The strong manufacturing infrastructure supporting oral pharmaceutical formulations has enabled domestic and international pharmaceutical companies to efficiently produce and distribute generic medications throughout the Kingdom. Furthermore, increasing outpatient visits, expanding healthcare coverage, and growing awareness of affordable treatment options continue to drive demand for oral generic drugs. Healthcare providers often prefer oral medications due to their ease of prescription, administration, and long-term patient compliance. As Saudi Arabia’s healthcare sector continues to expand and chronic disease prevalence increases, oral generic drugs are expected to maintain their dominant position within the pharmaceutical market.

Saudi Arabia Respiratory Generic Drugs Market

The respiratory generic drugs market in Saudi Arabia is witnessing steady growth due to the increasing prevalence of respiratory disorders, including asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary conditions. Environmental factors such as dust exposure, air pollution, and smoking habits contribute significantly to the growing burden of respiratory diseases across the country. As a result, demand for affordable respiratory medications and inhalation therapies has increased substantially. Pharmaceutical companies are expanding their portfolios of generic respiratory products, including metered-dose inhalers, dry powder inhalers, nebulized medications, and oral respiratory therapies. Although the development and manufacturing of respiratory generics involve technical complexities related to delivery devices and regulatory requirements, ongoing technological advancements are improving product accessibility and affordability. Government healthcare initiatives, reimbursement policies, and increased public awareness regarding respiratory health management continue to support market expansion. The growing focus on preventive healthcare and chronic disease management is expected to further strengthen demand for respiratory generic medications in Saudi Arabia.

Saudi Arabia Oncology Generic Drugs Market

The oncology generic drugs market in Saudi Arabia is expanding rapidly due to increasing cancer incidence rates and rising demand for cost-effective cancer treatment options. Oncology therapies often involve substantial healthcare expenditures, creating significant financial challenges for healthcare providers, insurers, and patients. Generic oncology drugs, including biosimilars and complex generic formulations, provide affordable alternatives while maintaining therapeutic effectiveness and treatment quality. Government healthcare funding programs, expanded insurance coverage, and increased investments in cancer diagnosis and treatment infrastructure have contributed to growing adoption of oncology generics. Furthermore, improvements in early cancer detection programs and increased awareness of cancer treatment options have expanded the patient population requiring long-term therapeutic interventions. Hospitals and healthcare institutions increasingly incorporate generic oncology products into treatment protocols to improve healthcare accessibility and manage treatment costs efficiently. As pharmaceutical companies continue to develop advanced oncology generics and biosimilars, this market segment is expected to play an increasingly important role in Saudi Arabia’s healthcare system.

Saudi Arabia Online Generic Drugs Market

The online generic drugs market in Saudi Arabia has experienced significant growth due to rapid digital transformation within the healthcare sector and increasing consumer preference for digital healthcare services. The expansion of e-pharmacy platforms, telemedicine services, and digital healthcare ecosystems has enabled patients to conveniently access affordable generic medications through online channels. Consumers increasingly utilize digital platforms to compare medication prices, obtain electronic prescriptions, and purchase pharmaceutical products with improved convenience and accessibility. The COVID-19 pandemic further accelerated the adoption of online healthcare services and contactless pharmaceutical distribution models throughout the Kingdom. Additionally, Saudi Arabia’s young, digitally connected population and increasing smartphone and internet penetration rates have created favorable conditions for the expansion of online pharmaceutical services. Government initiatives supporting healthcare digitalization and electronic health services continue to strengthen this market segment. As digital healthcare infrastructure continues to evolve, online distribution channels are expected to become an increasingly important component of Saudi Arabia’s generic drugs market.

Jeddah Generic Drugs Market

The generic drugs market in Jeddah is expanding steadily due to its position as a major commercial, healthcare, and logistics hub in Saudi Arabia. The city’s large and diverse population, combined with strong healthcare infrastructure, supports high demand for affordable medicines across both public and private sectors. Hospitals, retail pharmacies, and clinics in Jeddah increasingly rely on generic drugs to manage rising treatment costs, particularly for chronic diseases such as diabetes, hypertension, and cardiovascular conditions. The growth of private healthcare providers and medical tourism has further strengthened market demand for cost-effective pharmaceutical solutions. Additionally, government initiatives aimed at improving healthcare accessibility and promoting generic drug usage have encouraged wider adoption across the region. The presence of well-developed distribution networks and pharmaceutical companies also ensures consistent supply. As healthcare digitalization and awareness of affordable treatment options increase, Jeddah continues to emerge as a key market for generic drugs in Saudi Arabia.

Riyadh Generic Drugs Market

Riyadh represents the largest and most advanced generic drugs market in Saudi Arabia due to its role as the capital city and primary center for healthcare governance, policymaking, and pharmaceutical distribution. The city has a highly developed healthcare ecosystem, including major government hospitals, private medical institutions, and specialized clinics that heavily utilize generic medicines to optimize healthcare spending. Rising prevalence of chronic diseases and increasing patient population have significantly boosted demand for affordable treatment alternatives. Government healthcare programs and insurance systems in Riyadh actively promote the use of generic drugs to improve cost efficiency and ensure wider access to essential medicines. Additionally, strong regulatory oversight and pharmaceutical investments have supported the expansion of domestic and international generic drug manufacturers in the region. The city also benefits from advanced logistics infrastructure and digital healthcare systems, which enhance drug distribution efficiency. As healthcare modernization continues under Vision 2030, Riyadh is expected to remain the dominant hub for the generic drugs market in the Kingdom.

Dammam Generic Drugs Market

Dammam plays a significant role in Saudi Arabia’s generic drugs market due to its strategic location in the Eastern Province and its strong industrial and healthcare base. The city has a well-established healthcare infrastructure, including government hospitals, private clinics, and specialized medical centers that increasingly rely on generic medicines to reduce healthcare costs. High prevalence of chronic diseases such as diabetes, hypertension, and respiratory disorders has created sustained demand for affordable pharmaceutical products. Additionally, Dammam’s proximity to major industrial zones and oil and gas facilities contributes to workplace-related healthcare needs, further supporting drug consumption. Government initiatives aimed at expanding healthcare accessibility and promoting pharmaceutical localization have strengthened the presence of generic drug manufacturers and distributors in the region. Efficient transportation networks and logistics infrastructure ensure smooth distribution of medicines across the Eastern Province. As healthcare services continue to expand and patient awareness increases, Dammam is expected to remain an important regional market for generic drugs in Saudi Arabia.

Dhahran Generic Drugs Market

The generic drugs market in Dhahran is driven by its strong association with the energy sector, research institutions, and advanced healthcare facilities in Saudi Arabia’s Eastern Province. The presence of a large workforce in oil and gas industries has increased demand for affordable and effective healthcare solutions, particularly for chronic and occupational health conditions. Hospitals and healthcare centers in Dhahran frequently utilize generic drugs to manage treatment costs while ensuring high-quality patient care. The city also benefits from advanced medical infrastructure and research collaborations that support pharmaceutical innovation and adoption of cost-effective treatments. Government efforts to improve healthcare access and promote the use of generic medicines have further strengthened market growth. Additionally, increasing awareness among healthcare professionals and patients regarding the safety and effectiveness of generic drugs has improved acceptance levels. As healthcare modernization and industrial workforce needs continue to grow, Dhahran is expected to maintain steady demand for generic pharmaceutical products within the region.

Research Methodology of Saudi Arabia Generic Drugs Market

The Saudi Arabia Generic Drug Market was estimated using a combination of bottom-up and top-down approaches, secondary research, prescription-volume analysis, patient-based estimation, medicine-level assessment, company-level revenue analysis, pricing analysis, and data triangulation. The methodology considered generic medicines supplied through hospitals, pharmacies, clinics, government healthcare facilities, and other relevant channels.

1. Market Definition and Scope

The market was first defined to establish which medicines and revenues were included.

The Saudi Arabia Generic Drug Market was considered to include revenues generated from pharmaceutical products containing active pharmaceutical ingredients equivalent to those of established branded or reference medicines and marketed under generic names or generic formulations.

2. Secondary Research

Extensive secondary research was conducted to establish the underlying market variables.

Information was collected from:

• Saudi government healthcare agencies
• Saudi Food and Drug Authority
• Ministry of Health
• National healthcare statistics
• Pharmaceutical associations
• Pharmaceutical manufacturers
• Local distributors
• Hospital networks
• Pharmacy chains
• Company annual reports, etc.

The research focused on:

• Generic medicine approvals
• Prescription volumes
• Drug utilization
• Pharmaceutical expenditure
• Generic penetration
• Medicine prices
• Hospital procurement
• Pharmacy sales, etc.

3. Bottom-Up Market Estimation

A bottom-up approach was used as the primary market-sizing methodology.

The market was estimated by determining the volume of generic medicines sold and multiplying it by the average realized selling price.

The basic calculation was:

Generic Drug Volume × Average Revenue per Unit = Generic Drug Market Revenue

The individual values were subsequently aggregated to determine the total Saudi Arabian market.

4. Prescription-Based Estimation

Prescription volume was used as a key demand indicator.

The analysis considered:

• Number of prescriptions
• Generic prescription share
• Average units per prescription
• Repeat prescriptions
• Chronic disease prescriptions
• Acute disease prescriptions

The calculation was:

Total Prescriptions × Generic Prescription Share × Average Units per Prescription × Average Price per Unit

This approach helped estimate generic medicine consumption from the demand side.

5. Patient-Based Estimation

A patient-based methodology was used to validate prescription volumes.

The relevant patient population was estimated for major therapeutic categories.

The calculation was:

Disease Population × Diagnosed Population × Treatment Rate × Generic Utilization Rate × Average Annual Drug Spending

This approach was particularly useful for chronic conditions such as:

• Diabetes
• Hypertension
• Cardiovascular diseases
• Respiratory disorders
• Chronic neurological conditions

Patients receiving long-term medication were analyzed separately from those receiving short-duration treatments.

6. Therapeutic-Area Estimation

The market was estimated independently for major therapeutic areas.

For each category, the analysis considered:

• Disease prevalence
• Diagnosed patient population
• Treatment penetration
• Prescription volume
• Generic penetration
• Average medicine price
• Treatment duration

The calculation was:

Treated Patients × Generic Treatment Rate × Annual Generic Drug Spending per Patient

The individual therapeutic-area estimates were then aggregated.

7. Medicine-Level Estimation

Major generic medicines were assessed individually where reliable data were available.

The analysis considered:

• Active pharmaceutical ingredient
• Dosage form
• Strength
• Pack size
• Manufacturer
• Regulatory status
• Number of generic competitors
• Wholesale price
• Retail price
• Prescription volume

The revenue generated by each medicine was estimated and subsequently aggregated.

This approach helped account for substantial differences in pricing and demand between individual generic medicines.

8. Generic Penetration Estimation

Generic penetration was estimated separately across therapeutic categories and distribution channels.

The analysis considered:

• Physician prescribing behavior
• Generic substitution
• Medicine availability
• Price differences
• Government procurement
• Pharmacy substitution
• Hospital formularies
• Generic drug policies

The calculation was:

Relevant Drug Market × Generic Penetration Rate = Generic Drug Market

Different penetration assumptions were applied to hospital, retail, and government channels where evidence indicated different purchasing patterns.

9. Hospital Market Estimation

Hospital demand was estimated using pharmaceutical procurement and medicine-utilization patterns.

The analysis considered:

• Public hospitals
• Private hospitals
• Specialty hospitals
• Government healthcare facilities

The calculation was:

Hospital Drug Volume × Generic Share × Average Generic Drug Price

Hospital procurement data were used where available to validate the generic medicine volume and pricing assumptions.

10. Retail Pharmacy Market Estimation

Retail pharmacy demand was estimated using:

• Number of pharmacies
• Prescription volumes
• Generic dispensing rates
• Average units per prescription
• Average retail price

The calculation was:

Retail Generic Prescriptions × Average Units per Prescription × Average Retail Price

Pharmacy-level information and distributor data were used to validate the estimate.

11. Government Procurement Estimation

Government purchasing was analyzed separately because public-sector procurement could involve centralized tenders and different pricing structures.

The analysis considered:

• Government tenders
• Public hospitals
• Ministry of Health procurement
• Centralized purchasing
• Government healthcare programs

The calculation was:

Government Generic Drug Procurement Volume × Average Procurement Price

Tender prices were used as a validation benchmark for institutional generic medicine pricing.

12. Import and Local Manufacturing Analysis

Saudi Arabia's pharmaceutical supply structure was assessed to determine the source of generic medicines.

The analysis considered:

• Imported generic medicines
• Locally manufactured generics
• Contract manufacturing
• Pharmaceutical production facilities
• Active pharmaceutical ingredient imports

Import volumes and manufacturer activity were used to validate the estimated domestic consumption.

The market calculation was based on domestic sales and consumption, rather than simply adding import and production values together, which could result in double counting.

13. Average Selling Price Estimation

Average prices were estimated separately by:

• Therapeutic area
• Formulation
• Dosage
• Pack size
• Distribution channel
• Manufacturer

Pricing information was obtained from:

• Drug registration information
• Pharmacy prices
• Distributor information
• Government procurement records
• Manufacturer price lists
• Hospital procurement
• Industry interviews

Retail and institutional prices were differentiated because government and hospital procurement prices could differ substantially from retail prices.

14. Company-Level Revenue Analysis

Major generic pharmaceutical companies operating in Saudi Arabia were identified and analyzed.

The assessment included:

• Local pharmaceutical manufacturers
• Multinational generic manufacturers
• Regional pharmaceutical companies
• Contract manufacturers
• Pharmaceutical distributors

Company annual reports, product portfolios, Saudi operations, manufacturing capacity, and regional pharmaceutical revenues were reviewed.

Where companies sold both branded and generic medicines, only the estimated generic portion of revenue was included.

15. Product-Level Analysis

Individual generic products were reviewed to validate the market estimate.

The assessment considered:

• Generic drug name
• Active pharmaceutical ingredient
• Manufacturer
• Dosage form
• Strength
• Pack size
• Regulatory approval
• Retail price
• Procurement price
• Distribution channel

Product-level analysis helped establish realistic average prices and identify differences between high-volume and specialty generic medicines.

16. Top-Down Market Estimation

A top-down approach was applied as an independent validation method.

The broader Saudi pharmaceutical market was estimated first, followed by an assessment of the proportion attributable to generic medicines.

The calculation was:

Saudi Arabia Pharmaceutical Market × Generic Drug Share = Estimated Generic Drug Market

The generic share was determined using:

• Prescription data
• Generic penetration
• Drug approvals
• Government procurement
• Pharmacy utilization
• Generic substitution

The resulting figure was compared with the bottom-up estimate.

17. Supply-Side Validation

The supply side was analyzed through pharmaceutical manufacturers and distributors.

The assessment considered:

• Generic product portfolios
• Production capacity
• Sales revenues
• Distribution networks
• Product registrations
• Import volumes
• Local manufacturing

The aggregated supplier-side estimate was compared with the demand-side market calculation.

18. Demand-Side Validation

Demand was validated using patient and prescription information.

The calculation followed:

Population → Disease Population → Diagnosed Patients → Treated Patients → Prescriptions → Generic Utilization → Revenue

This demand-side estimate was compared with:

• Pharmaceutical sales
• Hospital procurement
• Pharmacy activity
• Company revenues
• Drug registration data

19. Reimbursement and Pricing Analysis

The analysis considered the effect of healthcare reimbursement and pricing structures on generic medicine demand.

The assessment included:

• Government healthcare coverage
• Private health insurance
• Hospital purchasing
• Patient out-of-pocket expenditure
• Pharmacy pricing
• Generic substitution

Average realized prices were used instead of relying exclusively on listed retail prices.

20. Avoiding Double Counting

Particular attention was given to avoiding double counting between:

• Manufacturer revenue
• Distributor revenue
• Pharmacy sales
• Hospital procurement
• Government purchases
• Imported medicines
• Locally manufactured medicines

For example, the same generic medicine could appear first as an imported product, then as distributor revenue, and finally as pharmacy sales. Only the appropriate end-market pharmaceutical revenue was included in the final calculation.

21. Forecast Estimation

The historical market estimate was used as the foundation for forecasting.

Future market development was assessed based on:

• Population growth
• Increasing chronic disease burden
• Expansion of healthcare infrastructure
• Growth in prescription medicine demand
• Increasing generic adoption
• Government pharmaceutical procurement
• Local pharmaceutical manufacturing
• Expansion of generic drug portfolios
• Healthcare policy developments
• Pharmaceutical localization initiatives

Separate assumptions were applied to retail, hospital, and government generic medicine demand.

22. Data Triangulation

The final Saudi Arabia Generic Drug Market estimate was established through three principal approaches:

Bottom-Up Approach

Generic Drug Volume × Average Realized Price

Top-Down Approach

Saudi Pharmaceutical Market × Generic Drug Share

Supply-Side Validation

Company Revenues + Drug-Level Analysis + Procurement Data

The results were compared and reconciled.

Where discrepancies occurred, assumptions relating to prescription volumes, generic penetration, drug prices, procurement, and patient populations were reassessed.

23. Final Market Calculation

The final estimate was then validated against prescription volumes, patient-based calculations, drug-level pricing, government procurement, pharmaceutical company revenues, import and local-production data and top-down market estimates.

Market Segmentation

Type

• Simple Generics
• Specialty Generics
• Biosimilars

Route of Administration

• Oral
• Injections

Therapeutic Area

• Infectious Diseases
• Respiratory
• Musculoskeletal Diseases
• Oncology
• Central Nervous System (CNS)
• Cardiovascular
• Others

Distribution Channel

• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

Cities

• Riyadh
• Jeddah
• Dammam
• Dhahran
• Jubail
• Khobar
• Tabuk
• Mecca
• Medina
• Rest of Cities

All the Key players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Sandoz Group AG
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.
• Aurobindo Pharma Ltd.
• Lupin Ltd.
• Hikma Pharmaceuticals PLC
• STADA Arzneimittel AG
• Dr. Reddy’s Laboratories Ltd.

Report Details: